SG10201902596TA - Novel methods of protein evolution - Google Patents

Novel methods of protein evolution

Info

Publication number
SG10201902596TA
SG10201902596TA SG10201902596TA SG10201902596TA SG10201902596TA SG 10201902596T A SG10201902596T A SG 10201902596TA SG 10201902596T A SG10201902596T A SG 10201902596TA SG 10201902596T A SG10201902596T A SG 10201902596TA SG 10201902596T A SG10201902596T A SG 10201902596TA
Authority
SG
Singapore
Prior art keywords
novel methods
protein evolution
methods
present
evolution
Prior art date
Application number
SG10201902596TA
Other languages
English (en)
Inventor
Jay Short
Original Assignee
Bioatla Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Llc filed Critical Bioatla Llc
Publication of SG10201902596TA publication Critical patent/SG10201902596TA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50Mutagenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2/00Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047Simultaneous synthesis of different peptide species; Peptide libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845Methods of identifying protein-protein interactions in protein mixtures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG10201902596TA 2010-07-16 2011-03-04 Novel methods of protein evolution SG10201902596TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36521610P 2010-07-16 2010-07-16

Publications (1)

Publication Number Publication Date
SG10201902596TA true SG10201902596TA (en) 2019-04-29

Family

ID=45469988

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201902596TA SG10201902596TA (en) 2010-07-16 2011-03-04 Novel methods of protein evolution
SG2013002274A SG187033A1 (en) 2010-07-16 2011-03-04 Novel methods of protein evolution

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013002274A SG187033A1 (en) 2010-07-16 2011-03-04 Novel methods of protein evolution

Country Status (9)

Country Link
US (3) US10106576B2 (fr)
EP (2) EP3435087B1 (fr)
CN (2) CN105924499B (fr)
AU (1) AU2011279747B2 (fr)
CA (1) CA2804746C (fr)
DK (2) DK2593797T3 (fr)
ES (2) ES2966088T3 (fr)
SG (2) SG10201902596TA (fr)
WO (1) WO2012009026A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3553089A1 (fr) 2012-05-10 2019-10-16 Bioatla, LLC Anticorps monoclonaux multispécifiques
CN113504375B (zh) * 2014-01-07 2024-01-09 生物蛋白有限公司 靶向直向同源物的蛋白
CN109696550B (zh) * 2017-10-20 2022-08-26 成都蓝瑙生物技术有限公司 用于脑中风的发光elisa体液样品稳定化用水溶液
WO2020227515A1 (fr) 2019-05-07 2020-11-12 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
WO2023023055A1 (fr) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions et procédés d'optimisation du tropisme de systèmes d'administration d'arn
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
CA3231523A1 (fr) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Lipides acycliques et leurs procedes d'utilisation
WO2023044483A2 (fr) 2021-09-20 2023-03-23 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer positif her2
WO2023092004A1 (fr) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions et méthodes pour le traitement de troubles liés à tau
WO2023122752A1 (fr) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Lipides contraints et procédés d'utilisation associés
WO2023196931A1 (fr) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. Lipides cycliques et nanoparticules lipidiques (npl) pour l'apport d'acides nucléiques ou de peptides destinés à être utilisés dans la vaccination contre des agents infectieux
WO2023220695A2 (fr) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions et procédés pour le traitement du cancer her2 positif
WO2024030976A2 (fr) 2022-08-03 2024-02-08 Voyager Therapeutics, Inc. Compositions et procédés permettant le franchissement de la barrière hémato-encéphalique

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
EP0359789B1 (fr) 1988-01-21 1993-08-04 Genentech, Inc. Amplification et detection de sequences d'acides nucleiques
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
US5604116A (en) 1992-11-24 1997-02-18 G. D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
US6562594B1 (en) 1999-09-29 2003-05-13 Diversa Corporation Saturation mutagenesis in directed evolution
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US6171820B1 (en) 1995-12-07 2001-01-09 Diversa Corporation Saturation mutagenesis in directed evolution
US20030219752A1 (en) * 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
CA2239686A1 (fr) * 1995-12-07 1997-06-12 Recombinant Biocatalysis, Inc. Procede de detection d'une activite enzymatique
US7033781B1 (en) 1999-09-29 2006-04-25 Diversa Corporation Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating
EP1361891A2 (fr) 2001-02-19 2003-11-19 MERCK PATENT GmbH Proteines artificielles presentant une immunogenicite reduite
EP1421203A4 (fr) * 2001-05-17 2005-06-01 Diversa Corp Nouvelles molecules de liaison a un antigene destinees a des applications therapeutiques, diagnostiques, prophylactiques, enzymatiques, industrielles et agricoles et procedes de generation et de criblage de telles molecules
US7647184B2 (en) * 2001-08-27 2010-01-12 Hanall Pharmaceuticals, Co. Ltd High throughput directed evolution by rational mutagenesis
KR20080073293A (ko) 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
US20090309617A1 (en) 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
WO2009059235A2 (fr) 2007-11-01 2009-05-07 Facet Biotech Corporation Vecteurs de présentation d'immunoglobulines
US8312249B1 (en) 2008-10-10 2012-11-13 Apple Inc. Dynamic trampoline and structured code generation in a signed code environment
SG177687A1 (en) * 2009-07-17 2012-02-28 Bioatla Llc Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
WO2011109726A2 (fr) * 2010-03-05 2011-09-09 Bioatla Llc Anticorps homologues multispécifiques
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives

Also Published As

Publication number Publication date
DK3435087T3 (da) 2023-11-27
US10106576B2 (en) 2018-10-23
US20130116125A1 (en) 2013-05-09
CN103003696A (zh) 2013-03-27
US10829513B2 (en) 2020-11-10
CA2804746A1 (fr) 2012-01-19
US20180362576A1 (en) 2018-12-20
US20210017221A1 (en) 2021-01-21
SG187033A1 (en) 2013-02-28
EP3435087A1 (fr) 2019-01-30
ES2741175T3 (es) 2020-02-10
AU2011279747B2 (en) 2015-07-16
AU2011279747A1 (en) 2013-01-10
CN105924499A (zh) 2016-09-07
EP2593797A4 (fr) 2014-01-08
DK2593797T3 (da) 2019-08-05
WO2012009026A3 (fr) 2012-09-07
EP2593797A2 (fr) 2013-05-22
ES2966088T3 (es) 2024-04-18
WO2012009026A2 (fr) 2012-01-19
CA2804746C (fr) 2022-01-11
EP2593797B1 (fr) 2019-05-08
CN103003696B (zh) 2016-06-01
CN105924499B (zh) 2020-09-15
US11639365B2 (en) 2023-05-02
EP3435087B1 (fr) 2023-11-08

Similar Documents

Publication Publication Date Title
SG10201902596TA (en) Novel methods of protein evolution
MX346700B (es) Metodo para mejorar el rendimiento de un polipeptido.
EP2534257A4 (fr) Procédés d'identification et d'isolement de cellules exprimant un polypeptide
MX339809B (es) Metodo para preparar anticuerpos con propiedades mejoradas.
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2013142859A3 (fr) Protéines de fusion de la protéine verte fluorescente superfolder et leur utilisation
MX348605B (es) Mejoramiento de la actividad de proteinas que requieren centros fe-s.
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
TR201909037T4 (tr) Yeni protein deamidaz.
MX346500B (es) Metodos y composiciones para inmunoterapia para enfermedad neural.
EP2516624A4 (fr) Lignée cellulaire 3m
MX2016000393A (es) Modificaciones de proteinas quimioenzimaticas de lisina utilizando transglutaminasa microbiana.
EA201401211A1 (ru) Улучшенные варианты фермента химозина
IN2015MN00027A (fr)
MX2018012550A (es) Composiciones y metodos para la deteccion de proteinas de celulas huesped.
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EP2534168A4 (fr) Préparation chimique de thioesters d'ubiquitine et modifications de ces derniers
WO2015112558A3 (fr) Peptides, dispositifs et procédés pour la détection d'anticorps d'anaplasma
GB0711424D0 (en) Recombinant transferrin mutants
WO2015030585A3 (fr) Procédés pour détecter des lysines ayant subi une modification post-traductionnelle dans un polypeptide
NZ596501A (en) Casb7439 constructs
WO2014170460A3 (fr) Procede de production de proteines de collagene issues d'eponges marines et organisme apte a produire lesdites proteines
NZ740471A (en) Improved soy protein crisps
NZ603942A (en) Vitronectin:keratinocyte growth factor chimeras